A Study of Propranolol to Treat Kaposi Sarcoma

A clinical study of propranolol for the treatment of Kaposi Sarcoma in children and adults. This study will be an open-label single armed treatment trial that will test the effectiveness and the safety of treating Kaposi Sarcoma with propranolol.

Trial Details

NCT ID
NCT05797662
Phase
PHASE2
Sponsor
AIDS Malignancy Consortium
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Propranolol
Locations (sample)
  • Buenos Aires, Argentina|-34.61315,-58.37723
  • Rio de Janeiro, Brazil|-22.90642,-43.18223
  • Salvador, Brazil|-12.97563,-38.49096
  • Mexico City, Mexico|19.42847,-99.12766
  • Kampala, Uganda|0.31628,32.58219

Key Eligibility Criteria

  • Pediatric (\< 18 years) and adult (≥ 18 years) participants with biopsy-proven and measurable Kaposi Sarcoma (KS) as defined in the KS Manual of Pr…
  • No urgent clinical indication for immediate cytotoxic chemotherapy. Participants who have received cytotoxic chemotherapy \> 4 weeks prior to scree…
  • \< 18 years:
  • 1A (Mild): disease limited to skin, flat oral mucosal lesions, and/or flesh colored subcutaneous nodules, total \<10 lesions.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →